Potencijalna uloga polifenolniog standardizovanog ekstrakta aronije (Aronia melanocarpa) na COVID-19 infekciju izazvanu SARS CoV-2 virusom i njegove kardiometaboličke komplikacije

  • Miroslav Mitrović Pharmanova doo Beograd i Hispa Srbija
  • Nebojša Tasić
  • Vladimir Lj. Jakovljević
  • Danijela Tasić
  • Nikola M. Mitrović
Ključne reči: polifenoli, fotinija, COVID-19, antivirusne supstance, metabolički sindrom, dodaci ishrani

Sažetak


Pandemija COVID-19 je obeležila vreme u kojem živimo. Do sada je zaraženo više od 167 miliona ljudi, a preko 3 miliona je umrlo. Povećanje kardiometaboličkih faktora rizika tokom COVID-19 je povećano, između ostalog i zbog izolacije i sedativnog načina života, kao i većeg unosa hrane. Srbija spada u grupu zemalja sa visokim kardiovaskularnim rizikom. Meta-analize su potvrdile vezu između težine kardiometaboličkih bolesti i razvoja ozbiljnijih kliničkih pojava COVID-19, dok je metabolički sindrom značajan induktor komplikacija bolesti. Endotelna disfunkcija kod pacijenata sa metaboličkim sindromom igra važnu ulogu u razvoju komplikacija COVID-19. Svaka aktivnost koja dovodi do smanjenja zapaljenskih procesa u endotelu i poboljšanja funkcije mikrocirkulacije je korisna. Polifenolna jedinjenja mogu da pokažu povoljan efekat tokom prevencije i lečenja COVID-19. Ekstrakt polifenola aronije melenokarpe je proizvod koji obećava. Klinička ispitivanja su dokazala snažno antiinflamatorno dejstvo, kao i visok stepen bakteriostatske i antivirusne aktivnosti, uključujući aktivnost protiv virusa SARS-CoV-2. Ekstrakt aronije u in vitro eksperimentima dovodi do direktne inaktivacije različitih virusnih kultura: gripa A (99,99%), virusa SARS-CoV-2 (96,98%) i adenovirusa (93,23%). Svojim sistemskim delovanjem ekstrakt aronije uspeva da značajno utiče na simptome i parametre metaboličkog sindroma, pa je kao takav logičan i efikasan izbor dodataka hrani u prevenciji i lečenju COVID-19, uključujući i simptome tokom post-COVID-19 perioda.

Reference

COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Baltimore: Johns Hopkins University of Medicine, 2021. (https://coronavirus.jhu.edu/map.html)

Korona virus COVID-19. Beograd: Ministarstvo zdravlja Republike Srbije, Institut za javno zdravlje “Dr Milan Jovanović Batut”, 2021. (https://covid19.rs)

Lin AL, Vittinghoff E, Olgin JE, Pletcher MJ, Marcus GM. Body weight changes during pandemic-related shelter-in-place in a longitudinal cohort study. JAMA Network Open 2021; 4(3): e212536.

Stress in America™ 2020. Washington, DC: American Pshylogocial Association, 2021. (https://www.apa.org/news/press/releases/stress/2020/report).

Rodríguez-Hidalgo AJ, Pantaleón Y, Dios I, Falla D. Fear of COVID-19, stress, and anxiety in university undergraduate students: a predictive model for depression. Front Psychol 2020. (doi: 10.3389/fpsyg.2020.591797).

Levkovich, Shinan-Altman S. Impact of the COVID-19 pandemic on stress and emotional reactions in Israel: a mixed-methods study. Int Health 2020. (doi: 10.1093/inthealth/ihaa08).

Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M, Rasoulpoor S, Khaledi-Paveh B. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Global Health 2020; 16: 57.

Nader Salari, Amin Hosseinian-Far, Rostam Jalali, Aliakbar Vaisi-Raygani, Shna Rasoulpoor, Masoud Mohammadi, Shabnam Rasoulpoor & Behnam Khaledi-Paveh. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Globalization and Health volume 16, Article number: 57 (2020)

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188.

Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol 2017; 960: 1–17.

Eckel RH. The metabolic syndrome. Lancet 2005; 365: 1415–28.

Metabolic Syndrome. Dallas: American Heart Association, 2021. (www.heart.org/en/health-topics/metabolic-syndrome).

Yanai H. Significant correlations of SARS-CoV-2 infection with prevalence of overweight/obesity and mean body mass index in the SARS-CoV-2 endemic countries. Cardiol Res 2020; 11: 412-4.

Yanai H. Metabolic syndrome and COVID-19. Cardiol Res 2020; 11: 360-5.

Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 2020; 14: 1463-5.

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020; 382: 1653-9.

Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999; 22(Suppl 3): C25-30.

Grover A, Oberoi M. A systematic review and meta analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother 2021; 7(2): 148-57.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417-8.

Gemelli Against COVID-19 Post-Acute Care Study Group. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res 2020; 32: 1613-20.

Tenforde MW, Kim SS, Lindsell CJ, et al.; IVY Network Investigators; CDC COVID-19 Response Team; IVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 993-8.

Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ 2020; 370: m3026.

Zhang T, Sun LX, Feng RE. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: 496-502. (in Chinese).

Kokotkiewicz A, Jaremicz Z, Luczkiewicz M. Aronia plants: a review of traditional use, biological activities, and perspectives for modern medicine. J Med Food 2010; 13:255-69.

Kim DH, Lim HW, Kim SH, et al. Antibacterial activity of crude Aronia melanocarpa (Black chokeberry) extracts against Bacillus cereus, Staphylococcus aureus, Cronobacter sakazakii, and Salmonella Enteritidis in various dairy foods: preliminary study. J Milk Sci Biotechnol 2018; 36: 155-63.

Dorneanu R, Cioanca O, Chifiriuc O, et al. Synergic benefits of Aronia melanocarpa-anthocyanin rich exstract and antibiotics used for urinary tract infections. Farmacia 2017; 65: 778-83.

Yiu CY, Chen SY, Chang LK, Chiu YF, Lin TP. Inhibitory effects of resveratrol on the Epstein-Barr virus lytic cycle. Molecules 2010; 15: 7115–24.

Zhang L, Li Y, Gu Z, et al. Resveratrol inhibits enterovirus 71 replication and pro-inflammatory cytokine secretion in rhabdosarcoma cells through blocking IKKs/NF- kB signaling pathway. PLoS One 2015; 10: e0116879.

Annunziata G, Maisto M, Schisano C, et al. Resveratrol as a novel anti-herpes simplex virus nutraceutical agent: an overview. Viruses 2018; 10: 473.

Lin CJ, Lin HJ, Chen TH, et al. Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PLoS One 2015; 10: e0117602.

Valcheva-Kuzmanova SV, Belcheva A. Current knowledge of Aronia melanocarpa as a medicinal plant. Folia Med (Plovdiv) 2006; 48: 11-7.

Park S, Kim JI, Lee I, et al. Aronia melanocarpa and its components demonstrate antiviral activity against influenza viruses. Biochem Biophys Res Commun 2013; 440: 14-9.

Kim Y, Narayanan S, Chang KO. Inhibition of influenza virus replication by plant-derived isoquercetin. Antiviral Res 2010; 88: 227-35.

Annunziata G, Jimenez-GarciaM, Capo X, et al. Microencapsulation as a tool to counteract the typical low bioavailability of polyphenols in the management of diabetes. Food Chem Toxicol 2020; 139: 111248.

Annunziata G, Sanduzzi Zamparelli M, Santoro C, et al. May polyphenols have a role against coronavirus infection? An overview of in vitro evidence. Front Med (Lausanne) 2020; 7: 240.

Mohammadi Pour P, Fakhri S, Asgary S, Farzaei MH, Echeverría J. The signaling pathways, and therapeutic targets of antiviral agents: focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front Pharmacol 2019; 10: 1207.

Frank B, Conzelmann C, Weil T, et al. Antiviral activity of plant juices and green tea against SARS-CoV-2 and influenza virus in vitro. bioRxiv 2020. (doi: https://doi.org/10.1101/2020.10.30.360545). (Preprint).

Hensel A, Bauer R, Heinrich M, et al. Challenges at the Time of COVID-19: opportunities and innovations in antivirals from nature. Planta Med 2020; 86: 659–64.

Mhatre S, Srivastava T, Naik S, Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: a review. Phytomedicine 2021; 85: 153286.

Chu AJ. Cardioprotection by bioactive polyphenols: a strategic view. Austin J Cardiovasc Dis Atherosclerosis 2018; 5: 1034.

Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2009; 2: 270–8.

Denev PN, Kratchanov CG, Ciz M, Lojek A, Kratchanova MG. Bioavailability and antioxidant activity of Black chokeberry (Aronia melanocarpa) polyphenols: in vitro and in vivo evidences and possible. mechanisms of action: a review. Compr Rev Food Sci Food Saf 2012; 11: 471-5.

Burton-Freeman B, Brzeziński M, Park E, Sandhu A, Xiao D, Edirisinghe I. A selective role of dietary anthocyanins and flavan-3-ols in reducing the risk of type 2 diabetes mellitus: a review of recent evidence. Nutrients 2019; 11: 841.

Sertifikat analize Alixir 400 PROTECT, broj 720/19. Beograd: Pharmanova d.o.o., 2019.

Jakovljevic V, Milic P, Bradic J, et al. Standardized Aronia melanocarpa extract as novel supplement against metabolic syndrome: a rat model. Int J Mol Sci 2018; 20: 6.

Skarpańska-Stejnborn A, Basta P, Sadowska J, Pilaczyńska-Szcześniak L. Effect of supplementation with chokeberry juice on the inflammatory status and markers of iron metabolism in rowers. J Int Soc Sports Nutr 2014; 11: 48.

Tasic N, Jakovljevic VLJ, Mitrovic M, et al. Black chokeberry Aronia melanocarpa extract reduces blood pressure, glycemia and lipid profile in patients with metabolic syndrome: a prospective controlled trial. Mol Cell Biochem 2021. (doi: 10.1007/s11010-021-04106-4).

Yang L, Ling W, Du Z, Chen Y, Li D, Deng S, Liu Z, Yang L. Effects of anthocyanins on cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2017; 8: 684-93.

Alixir 400 PROTECT. Rešenje o upisu u Registar dijetetskih proizvoda Ministarstva zdravlja Republike Srbije, broj 14313/2019 od 22.04.2019. Beograd: Pharmanova d.o.o., 2019.

Objavljeno
2021/11/25
Rubrika
Pregledni članak